A5090840695- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- DNA Repair Mechanisms
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- CRISPR and Genetic Engineering
- Renal cell carcinoma treatment
- Molecular Biology Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Ovarian function and disorders
- Cervical Cancer and HPV Research
- Hypothalamic control of reproductive hormones
- Cancer-related Molecular Pathways
- Reproductive Biology and Fertility
- Prostate Cancer Treatment and Research
- Ferroptosis and cancer prognosis
- Nutrition and Health in Aging
- Estrogen and related hormone effects
- Immune Cell Function and Interaction
- Hematological disorders and diagnostics
- Gynecological conditions and treatments
- Evolution and Genetic Dynamics
University of Washington
2015-2025
University of Washington Medical Center
2012-2024
Alaska Women's Cancer Care
2024
Seattle University
2023-2024
Mayo Clinic in Florida
2024
Gynecologic Oncology Group
2011-2023
Fred Hutch Cancer Center
2023
Woman's Cancer Foundation
2014-2020
Virginia Mason Medical Center
2019
Medical Genetics Center
2013
Abstract Purpose: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact somatic BRCA1/2 mutations in other homologous recombination DNA repair genes is uncertain. Experimental Design: Using targeted capture massively parallel genomic sequencing, we assessed 390 for loss-of-function 30 genes, including BRCA1, BRCA2, 11 the pathway. Results: Thirty-one percent had a deleterious (24%) and/or (9%) mutation one or more...
Inherited loss-of-function mutations in BRCA1 and BRCA2 other tumor suppressor genes predispose to ovarian carcinomas, but the overall burden of disease due inherited is not known. Using targeted capture massively parallel genomic sequencing, we screened for germ-line 21 DNA from women with primary ovarian, peritoneal, or fallopian tube carcinoma. Subjects were consecutively enrolled at diagnosis selected age family history. All classes mutations, including point large deletions insertions,...
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
Abstract BACKGROUND: Uterine serous carcinoma (USC) is not recognized as part of any defined hereditary cancer syndrome, and its association with breast ovarian Lynch syndrome are uncertain. METHODS: Using targeted capture massively parallel genomic sequencing, 151 subjects USC were assessed for germline mutations in 30 tumor suppressor genes, including BRCA1 (breast 1, early onset), BRCA2 , the DNA mismatch repair genes ( MLH1 [mutL homolog 1], MSH2 [mutS 2], MSH6 PMS2 [postmeiotic...
Background: Precision medicine relies on mutational profiling, but clinical actionability remains limited for many cancer patients. We evaluated the feasibility and of ex-vivo drug sensitivity testing across solid tumors, focusing rare cancers. This study uses PARIS® CLIA-certified test, assessing patient-derived tumor cells (PDTCs) responses to a broad oncology panel. Methods: Tumor specimens (biopsies, fluids, or surgical samples) were shipped our laboratory arrive within 48h cultured in...
PURPOSE NCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, MEK1/2 inhibitor, in Neurofibromatosis 1 ( NF1[S1] or GNA11/Q [S2]) altered tumors. METHODS Eligible had tumors deleterious inactivating NF1 mutations by the customized Oncomine AmpliSeq panel. Prior MEK inhibitor was excluded. Glioblastomas (GBMs) were permitted, including...
This pilot study describes a relationship between insulin resistance and μ-opioid neurotransmission in limbic appetite mood-regulating regions women with polycystic ovary syndrome (PCOS), suggesting that insulin–opioid interactions may contribute to behavioral reproductive pathologies of PCOS. We found [1] patients PCOS who are insulin-resistant (n = 7) had greater receptor availability (nondisplaceable binding potential) than controls 5); [2] was correlated severity resistance; [3]...
Current screening methods for ovarian cancer (OC) have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultra-deep sequencing the detection of disseminated OC cells has emerged as promising tool, but this approach not been tested early-stage disease or non-serous histologies. In addition, lavages carry multiple background mutations, significance which is poorly understood. was collected preoperatively 34 patients undergoing surgery suspected...
Intraepithelial fallopian tube neoplasia is thought to be a precursor lesion high-grade serous carcinoma of the Müllerian adnexae, particularly in women with BRCA1 or BRCA2 mutations. This association has led recommendations assess tubes for intraepithelial atypia. However, diagnostic reproducibility diagnosis unclear. In this study, 2 gynecologic pathologists independently evaluated sections from sample (N=198, 623 slides) undergoing salpingectomy. A total 101 (54%) were risk-reducing...
The objectives of this study were to describe the patterns and duration primary recurrent treatment in patients with ovarian cancer (OC) harboring germline BRCA1 BRCA2 (BRCA) mutations. A retrospective review BRCA mutation carriers advanced, high-grade OC diagnosed between 2004 2014 at least 3 years follow-up (or until death) was undertaken. Descriptive statistics calculated a Swimmer's Plot used depict disease course. Forty (26 BRCA1, 14 BRCA2) identified. Mean age 54 (range 32–77). All had...
<h3>Introduction/Background</h3> Dostarlimab+carboplatin-paclitaxel demonstrated PFS and OS benefits vs carboplatin-paclitaxel in patients with primary advanced or recurrent endometrial cancer (pA/rEC). Here, we report on the management of immune-related adverse events (irAEs) RUBY (NCT03981796) trial. <h3>Methodology</h3> Patients pA/rEC were randomized 1:1 to dostarlimab 500 mg, placebo, plus carboplatin AUC 5 paclitaxel 175 mg/m2 Q3W for 6 cycles, followed by 1000 Q6W up 3 years. AEs...